Literature DB >> 17175481

Paroxysmal nocturnal hemoglobinuria superimposed with preeclampsia.

Mann-Ling Chen1, Chen-Hsiang Yu, Fong-Ming Chang, Pao-Lin Kuo.   

Abstract

OBJECTIVE: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder characterized by complement-mediated intravascular hemolysis. As maternal complication of PNH is already severe, it becomes much more complex when preeclampsia is superimposed. We present a case of PNH superimposed with severe preeclampsia in the third trimester. CASE REPORT: A 30-year-old, gravida 1, para 0, woman had PNH, diagnosed at the age of 17. Her PNH was stable under medication. In 2004, she conceived and had prenatal care at our hospital. At 35 weeks of gestation, preeclampsia with elevated blood pressure and proteinuria were superimposed and managed with close surveillance. A live male baby was delivered vaginally at 38 weeks of gestation. During parturition, her blood pressure increased to 180/100 mmHg. Thrombocytopenia, hyponatremia, hyperkalemia, hypoalbuminemia, elevated liver enzymes and lactate dehydrogenase were also noted. Preeclampsia continued to postpartum and eventually disappeared.
CONCLUSION: The most frequent causes of PNH-related fetomaternal morbidity and mortality are hemolysis and thrombosis. The situation becomes even more complicated when PNH is superimposed with preeclampsia. Appropriate clinical surveillance, awareness of the potential risks of hemolysis and thrombosis, as well as evaluation of fetal wellbeing are essential.

Entities:  

Mesh:

Year:  2006        PMID: 17175481     DOI: 10.1016/S1028-4559(09)60242-4

Source DB:  PubMed          Journal:  Taiwan J Obstet Gynecol        ISSN: 1028-4559            Impact factor:   1.705


  2 in total

1.  Dialysis for severe hyponatraemia in preeclampsia.

Authors:  Annemarie Hennessy; Ian Hill
Journal:  Obstet Med       Date:  2010-03-04

Review 2.  Successful anticoagulant therapy for two pregnant PNH patients, and prospects for the eculizumab era.

Authors:  Yasuyoshi Morita; Jun-ichi Nishimura; Takahiro Shimada; Hirokazu Tanaka; Kentaro Serizawa; Yasuhiro Taniguchi; Mitsuhiro Tsuritani; Yuzuru Kanakura; Itaru Matsumura
Journal:  Int J Hematol       Date:  2013-03-02       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.